Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B

Gut

Volumn 51, Issue 4, 2002, Pages 597-599

  Lim, S G ^a   Wai, C T ^a   Rajnakova, A ^a   Kajiji, T ^a   Guan, R ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FAMCICLOVIR; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; VIRUS DNA;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; LIVER BIOPSY; MALE; MUTATION; PRIORITY JOURNAL; PROTHROMBIN TIME; VIRUS REACTIVATION;

2-AMINOPURINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BILIRUBIN; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MUTATION; RECURRENCE; VIRUS ACTIVATION;

EID: 0036785331     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.51.4.597     Document Type: Article

References (14)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine or chronic hepatitis B. Asia Hepatitis Lamivudine Group. N Engl J Med 1998;339:61-8.
2. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e-antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatotogy 1999;29:889-96.
3. Gunther S, von Breunig F, Santantonio T, et al. Absence of mutations in the YMDD/motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999;30:101-41.
4. Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999;58:101-41.
5. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomised dose-ranging study. Gastroenterology 1997;13:1258-63.
6. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
7. Honkoop P, de Man RA, Niesters HG. Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy. Ann Intern Med 1998;128:697.
8. Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
9. Honkoop P, de Man RA, Niesters HG, et al. Hepatitis B reactivation after lamivudine. Lancet 1995;346:1156-7.
10. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-7.
11. Hwang SL, Lee SD, Lu RN, et al. Comparison of three different hybidization assays in the quantitative measurement of serum hepatitis B virus DBA. J Virol Methods 1996;62:123-9.
12. Liaw YF, Chen JJ, Chen TJ. Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. Liver 1990;10:177-84.
13. Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen cariers: a placebo-controlled trial. Hepatology 1997;25:241-4.
14. Myers RP, Chaudhary R, Fonseca K, et al. Fatal hepatic decompensation in a patient with hepatitis B cirrhosis following famciclovir withdrawal. Can J Gastroenterol 2000;14:725-7.